JAK1 and melanoma: In melanoma, loss-of-function JAK1/JAK2 mutations were discovered in a minority of patients after relapse on the anti-PD-1 treatment pembrolizumab; therefore, it is a potential avenue of acquired resistance to immune checkpoint blockade [30].